House Ways and Means Committee
February 12, 2026
House Bill 400 – *Biotechnology Investment Incentive Tax Credit – Conversion to Grant Program*
**POSITION: SUPPORT**

The Maryland Tech Council (MTC), with over 800 members, is the State's largest association of technology companies. Our vision is to propel Maryland to be the country's number one innovation economy for life sciences and technology. MTC brings the State's life sciences and technology communities into a single, united organization that empowers members to achieve their goals through advocacy, networking, and education. On behalf of MTC, we submit this letter of **support** for House Bill 400.

Maryland's life sciences and biotechnology sectors are among the fastest-growing engines of innovation in our state, representing thousands of companies and tens of thousands of high-paying jobs. These industries drive economic growth, attract private capital, and expand the State's global leadership in cutting-edge research and commercialization. In line with our advocacy priorities, Maryland must continue to support policies that strengthen the innovation economy and attract investment to emerging technology sectors.

House Bill 400 transitions the existing Biotechnology Investment Incentive Tax Credit into a Grant Program, with clear disbursement timelines and greater predictability for investors. This modernization will help reduce barriers to capital for early-stage biotechnology companies by providing timely and structured financial incentives. For innovative startups that often operate years before revenue generation, converting tax credits into direct grants improves certainty and catalyzes investment in Maryland-based bioscience ventures.

Support for this bill aligns squarely with MTC's goal of making Maryland a competitive place for life sciences innovation:

- It encourages investment in early-stage bioscience companies, which are critical to the State's innovation ecosystem.
- It supports job creation and commercialization of cutting-edge technologies that benefit patients and communities.
- It enhances Maryland's ability to attract and retain investors who seek clarity and stability in public incentives.

In a competitive regional environment where neighboring states actively court biotech capital, maintaining and strengthening investment incentives is essential to sustaining Maryland's leadership in this strategic industry.

For these reasons, the MTC respectfully urges a **favorable report** on House Bill 400.

**For more information call**:
Andrew G. Vetter
J. Steven Wise
Danna L. Kauffman
Christine K. Krone
410-244-7000